Össur: Incremental positive shifts in 2024 - ABG

Q4e: Tuesday, 30 January at 8:00 CET
Healthy 2024 with 6% organic growth and solid margin expansion
Fair value reiterated at DKK 26-40


Q4 Tuesday 30 Jan 08:00, CC 09:00 CET

We are looking for Ossur to report Q4 sales of USD 217.7m (+15% reported growth), some 5% above company-collected Consensus at USD 207.3m. We are inline with consensus on organic growth (~6%), which leaves our higher estimate driven by lower-quality M&A and FX assumptions. We are looking for EBITDA pre-items of USD 44.3m, +6% vs. consensus, likely due to the higher top-line. We assume a modest slowing of growth in the key Prosthetics business of 8% organically (12% in Q3), which still assumes healthy market share gains.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/ossur/Equity-research/2024/1/ossur---incremental-positive-shifts-in-2024/